Literature DB >> 21429565

Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.

Kazuo Kawasugi1, Hideo Wada, Tsuyoshi Hatada, Kohji Okamoto, Toshimasa Uchiyama, Shigeki Kushimoto, Yoshinobu Seki, Takashi Okamura, Tsutomu Nobori.   

Abstract

Patients with suspected disseminated intravascular coagulation (DIC) were prospectively evaluated for various types of underlying diseases, and the usefulness of hemostatic markers were examined for each patient with DIC due to various underlying diseases. The main underlying disease of DIC was infectious diseases, hematologic malignancies, and solid tumors, and a high resolution rate from DIC was observed in obstetric diseases and hematologic malignancies. The diagnosis of DIC was related to a poor outcome in trauma/burn victims and those with infectious disease. In the main underlying disease, it is suggested that DIC would be excluded in patients with hematologic malignancies or solid tumors with a platelet count of more than 100,000/μl and in the patients with an FDP of less than 10 μg/ml, and fibrinogen of less than 100mg/dl, suggesting the presence of DIC. The prothrombin time was a sensitive marker, but fibrinogen levels were not sensitive for DIC due to infectious diseases. The plasmin plasmin inhibitor complex in hematologic malignancy, and soluble fibrin monomer complex, antithrombin and thrombomodulin in patients with infectious disease, were sensitive markers for the diagnosis of DIC. Although hemostatic markers were useful for the diagnosis of DIC, the usefulness varied depending on the different underlying diseases.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21429565     DOI: 10.1016/j.thromres.2011.02.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  14 in total

Review 1.  Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review.

Authors:  B T Samuelson Bannow; B A Konkle
Journal:  Thromb Res       Date:  2018-01-31       Impact factor: 3.944

2.  Intraductal papillary neoplasm of intrahepatic bile ducts complicated by chronic disseminated intravascular coagulation and thrombosis: A case report.

Authors:  Ming Xiao; Aijun Sun; Fan Yu; Ying Xiao; Lihong Li; Dongyan Shen; Canhong Xiang; Jiahong Dong
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 3.  Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines.

Authors:  Hideo Wada; Takeshi Matsumoto; Yoshiki Yamashita
Journal:  J Intensive Care       Date:  2014-02-20

Review 4.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Authors:  Hidesaku Asakura; Hoyu Takahashi; Toshimasa Uchiyama; Yutaka Eguchi; Kohji Okamoto; Kazuo Kawasugi; Seiji Madoiwa; Hideo Wada
Journal:  Thromb J       Date:  2016-09-28

5.  Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.

Authors:  Kentaro Nakano; Kumiya Sugiyama; Hideyuki Satoh; Hajime Arifuku; Takayoshi Fujimatsu; Naruo Yoshida; Hiroyoshi Watanabe; Shingo Tokita; Tomoshige Wakayama; Masamitsu Tatewaki; Ryosuke Souma; Hiroyuki Masuda; Kenya Koyama; Hirokuni Hirata; Yasutsugu Fukushima
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

6.  Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.

Authors:  Kota Ouchi; Shin Takahashi; Sonoko Chikamatsu; Shukuei Ito; Yoshikazu Takahashi; Sadayuki Kawai; Akira Okita; Yuki Kasahara; Yoshinari Okada; Hiroo Imai; Keigo Komine; Ken Saijo; Masahiro Takahashi; Hidekazu Shirota; Masanobu Takahashi; Makio Gamoh; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2018-03-07       Impact factor: 3.402

7.  Risk factors and treatments for disseminated intravascular coagulation in neonates.

Authors:  Hayato Go; Hitoshi Ohto; Kenneth E Nollet; Nozomi Kashiwabara; Kei Ogasawara; Mina Chishiki; Shun Hiruta; Ichiri Sakuma; Yukihiko Kawasaki; Mitsuaki Hosoya
Journal:  Ital J Pediatr       Date:  2020-04-29       Impact factor: 2.638

8.  Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection.

Authors:  Qute Choi; Ki Ho Hong; Ji-Eun Kim; Hyun Kyung Kim
Journal:  Ann Lab Med       Date:  2014-02-13       Impact factor: 3.464

9.  [How I treat disseminated intravascular coagulation].

Authors:  Y Hu; Y D Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14

10.  Assessment of bleeding in patients with disseminated intravascular coagulation after receiving surgery and recombinant human soluble thrombomodulin: A cohort study using a database.

Authors:  Takuhiro Yamaguchi; Yukio Kitajima; Yasuhiro Miyauchi; Kazutoshi Izawa; Masakazu Tanaka; Masatada Hirata; Yasunari Sadatsuki; Yoshihiro Ogawa
Journal:  PLoS One       Date:  2018-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.